Developing new treatments for neuroinflammatory disorders
NeuroTherapia is a clinical stage company developing new treatments for neuroinflammatory disorders.
Neuroinflammation has now been recognized to play a key role in a range of neurologic disorders such as Alzheimer’s disease (AD), neuropathic pain, multiple sclerosis and ALS. The Company’s lead product, NTRX-07, is a highly selective cannabinoid type 2 (CB2) receptor agonist with demonstrated CNS activity that targets CB2 receptors on microglia, which significantly reduces the expression of inflammatory agents resulting in neuronal survival and activation.
The pre-clinical efficacy of NTRX-07 has been established in multiple models of Alzheimer’s Disease and neuropathic pain.
NeuroTherapia has completed Phase I clinical studies in healthy volunteers which demonstrated the safety of NTRX-07 at doses predicted to be efficacious. The Company will initiate a 28-day Phase II clinical study in AD patients in 2023.